Rheumatology Advance Access originally published online on December 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2004; 43: 416-422
Rheumatology Vol. 43 No. 4 (c) British Society for Rheumatology 2004; all rights reserved
Basic Science |
Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells
Departamento de Biología Celular, Facultad de Biología, Universidad Complutense de Madrid and 1Servicio de Reumatología y Unidad de Investigación, Hospital 12 de Octubre, Madrid, Spain.
Correspondence to: R. P. Gomariz, Departamento de Biología Celular, Facultad de Biología, Universidad Complutense de Madrid, 28040 Madrid, Spain. E-mail: gomariz{at}bio.ucm.es
Objective. Vasoactive intestinal peptide (VIP) has demonstrated beneficial effects in several murine models of immune-mediated inflammation by inhibiting both the inflammatory and the autoimmune components of the disease. We investigate its potential to modulate the release of proinflammatory cytokines and chemokines by human synovial cells from patients with rheumatoid arthritis (RA).
Methods. Fresh suspensions of synovial tissue cells (STC) or cultured fibroblast-like synoviocytes (FLS) were obtained from patients with RA or osteoarthritis (OA). The effects of VIP on basal or tumour necrosis factor 
(TNF-)-stimulated production of CCL2 (MCP-1, monocyte chemotactic protein 1), CXCL8 [interleukin (IL)-8], IL-6 and TNF- were studied by specific ELISAs (enzyme-linked immunosorbent assays). The mRNAs for CCL2, CXCL8 and IL-6 in FLS were analysed by real-time reverse transcription–polymerase chain reaction.
Results. VIP at 10 nM down-regulated chemokine production by STC and FLS from RA and OA patients. VIP also down-regulated the expression of mRNAs for CCL2, CXCL8 and IL-6. The effects of VIP were more clearly detected in RA samples and after stimulation with TNF-.
Conclusion. Our observations confirm that the proposed anti-inflammatory actions of VIP in murine models also apply to human synovial cells ex vivo. Further studies are encouraged to evaluate the use of VIP as a potential therapy for chronic inflammatory joint diseases.
KEY WORDS: VIP, Rheumatoid arthritis, CXCL8, CCL2, TNF-, IL-6, Synoviocytes
MGJ and BS contributed equally to this work.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Roca, L. Larocca, M. Calafat, J. Aisemberg, R. Meiss, A. M Franchi, and C. P. Leiros Reduced nitric oxide synthase and cyclo-oxygenase activity in the uterus of non-obese diabetic mice. Reproduction, December 1, 2006; 132(6): 931 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gutierrez-Canas, Y. Juarranz, B. Santiago, A. Arranz, C. Martinez, M. Galindo, M. Paya, R. P. Gomariz, and J. L. Pablos VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts Rheumatology, May 1, 2006; 45(5): 527 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sarkar, I. V. Lebedeva, L. Emdad, D.-c. Kang, A. S. Baldwin Jr., and P. B. Fisher Human Polynucleotide Phosphorylase (hPNPaseold-35): A Potential Link between Aging and Inflammation Cancer Res., October 15, 2004; 64(20): 7473 - 7478. [Abstract] [Full Text] [PDF]
|
|